Patents Assigned to Adarga, LLC
  • Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy
    Patent number: 12508271
    Abstract: The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, and salivary glands, which represent sites of off-target binding and toxicity for PSMA-targeted prostate cancer imaging agents and therapies. Accordingly, the 2-PMPA prodrugs can be used to pretreat, bind to, and shield the kidney and salivary glands from PSMA-targeted cytotoxic or radiotherapy.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 30, 2025
    Assignees: The Johns Hopkins University, Adarga, LLC
    Inventors: Barbara Slusher, Michael Nedelcovych, Rana Rais, Clemens Kratochwil